BioXcel Therapeutics files for Chapter 11, agrees to sell assets to Teva
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
August 28, 2026 6:00 AM EDTBioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders
Teva Pharmaceuticals to serve as stalking horse bidder in a court-supervised 363 auction process
BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations
NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (BioXcel Therapeutics or the Company), a biopharmaceutical company built on artificial intelligence (AI) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement... More
